Parallel Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q3 | – | Sell |
-2,835
| Closed | -$521K | – | 3409 |
|
|
2021
Q2 | $521K | Buy |
2,835
+296
| +12% | +$50.8K | 0.02% | 376 |
|
|
2021
Q1 | $388K | Buy |
2,539
+96
| +4% | +$14.8K | 0.02% | 425 |
|
|
2020
Q4 | $382K | Sell |
2,443
-203
| -8% | -$26.1K | 0.02% | 383 |
|
|
2020
Q3 | $303K | Sell |
2,646
-396
| -13% | -$42.7K | 0.02% | 421 |
|
|
2020
Q2 | $341K | Sell |
3,042
-1,766
| -37% | -$187K | 0.02% | 384 |
|
|
2020
Q1 | $431K | Buy |
4,808
+1,265
| +36% | +$124K | 0.03% | 278 |
|
|
2019
Q4 | $383K | Buy |
3,543
+847
| +31% | +$90.6K | 0.03% | 343 |
|
|
2019
Q3 | $264K | Buy |
2,696
+50
| +2% | +$5.64K | 0.02% | 402 |
|
|
2019
Q2 | $347K | Sell |
2,646
-229
| -8% | -$29.5K | 0.03% | 318 |
|
|
2019
Q1 | $389K | Buy |
2,875
+162
| +6% | +$20.1K | 0.04% | 263 |
|
|
2018
Q4 | $264K | Buy |
2,713
+1,929
| +246% | +$228K | 0.04% | 306 |
|
|
2018
Q3 | $109K | Buy |
784
+53
| +7% | +$6.65K | 0.01% | 582 |
|
|
2018
Q2 | $90K | Buy |
731
+437
| +149% | +$51.1K | 0.01% | 571 |
|
|
2018
Q1 | $33K | Buy |
294
+58
| +25% | +$6.93K | 0.01% | 845 |
|
|
2017
Q4 | $28K | Sell |
236
-192
| -45% | -$23.4K | ﹤0.01% | 896 |
|
|
2017
Q3 | $49K | Sell |
428
-97
| -18% | -$13.2K | 0.01% | 689 |
|
|
2017
Q2 | $72K | Sell |
525
-130
| -20% | -$15.1K | 0.01% | 584 |
|
|
2017
Q1 | $85K | Buy |
655
+320
| +96% | +$41.3K | 0.02% | 497 |
|
|
2016
Q4 | $41K | Buy |
+335
| New | +$41K | 0.01% | 654 |
|
Other funds holding ALXN
BCI
NICM
TAIM
RG
CFO
MAM